At the high concentrations used in medicine, antibiotics exert strong selection on bacterial populations 31 for the evolution of resistance. However, these lethal concentrations may not be representative of the 32 concentrations bacteria face in soil, a recognition that has lead to questions of the role of antibiotics in 33 soil environments as well as the dynamics of resistance evolution during sub-lethal challenge. Here 34 we examine the evolution of resistance to sub-MIC concentrations of streptomycin in the filamentous 35 soil bacterium Streptomyces coelicolor. First, we show that spontaneous resistance to streptomycin 36 causes an average fitness deficit of ~21% in the absence of drugs; however, these costs are eliminated 37 at concentrations as low as 1/10 the MIC of susceptible strains. Using experimental evolution, we 38 next show that resistance readily evolves at these non-lethal doses. More important, S. coelicolor 39 resistance that evolves at sub-MIC streptomycin is cost-free. Whole-genome analyses reveal that sub-40 MIC evolved clones fix a distinct set of mutations to those isolated at high drug concentrations. Our 41 results broaden the conditions under which resistance can evolve in nature and suggest that the long-42 term persistence of these strains is facilitated by the absence of pleiotropic fitness costs. Finally, our 43 data cast doubt on arguments that low-concentration antibiotics in nature are signals, instead 44 supporting models that resistance evolves in response to antibiotics used as weapons. 45 46 47 49
Evolving resistance at sub-MIC antibiotics Introduction concentration (MIC) of the susceptible strain and the MIC of the resistant strain 14 . However, while 77 this model correctly identifies the MIC as the threshold where resistant cells persist and susceptible 78 cells die, it fails to account for the fact that below the MIC the two cell types are not otherwise 79 competitively equivalent 8 . Indeed, susceptible cells can be significantly harmed by non-lethal, sub-80 MIC, antibiotics and these negative effects on growth can markedly increase the range of drug 81 concentrations where resistant cells are selected 6 . Of equal importance, the antibiotic concentration 82
where resistance evolves can have crucial implications for the type of resistance that evolves 8, 15 . 83 84 While antibiotic resistance that evolves at high concentrations often has a significant cost in terms of 85 bacterial fitness 1 , recent studies have predicted that this cost will not be evident for resistance that 86 emerges at low drug concentrations 6, 8, 16 . The reasons for this can be intuitively explained as follows: 87 while resistant cells above the MIC gain an absolute fitness advantage against susceptible strains, 88 below the MIC, resistant cells and susceptible cells will compete with one another. Accordingly, the 89 success of resistant strains below the MIC will be determined both by their ability to withstand the 90 effects of drug exposure and also their intrinsic competitiveness relative to susceptible cells. Strains 91 with costly resistance may therefore fail to outcompete susceptible strains, while strains with no-cost 92 resistance will thrive. As a consequence of these lower costs, it is furthermore predicted that 93 resistance that evolves at sub-MIC antibiotic concentrations will persist when growing in 94 environments without drugs, whereas strains with costly resistance may be outcompeted 17 . 95 128, 192 and 256 µg ml -1 streptomycin sulfate (Sigma, USA). Plates were incubated at 30 °C for 4 133 days. The MIC was set to the lowest concentration of antibiotic yielding no visible growth. To 134 investigate the level of streptomycin resistance in nature, we determined the MIC of a collection of 85 135
Streptomyces strains isolated from soil collected from the Himalaya in Nepal and Qinling Mountains 136 in China 22 . MICs were estimated as described above by spotting 1 ul of a 100-fold diluted spore 137 stock. 138 139 Spontaneous streptomycin resistance 140 Spontaneous streptomycin resistant clones were isolated from the WT strain by plating 10 9 spores 141 onto SFM agar containing 2, 4, 8 or 16 µg ml -1 streptomycin. After 2-3 days of growth, random single 142 colonies were selected from independent plates from each streptomycin concentration and then 143 restreaked onto a plate containing the same concentration of streptomycin as the selection plate. Spore 144 stocks of these single colonies were collected as outlined above and stored at -20°C . 145 146 Experimental evolution at sub-MIC streptomycin 147
To investigate the evolution and costs of streptomycin resistance at sub-MIC concentrations of 148 streptomycin, we serially transferred six replicate populations for ~500 generations on plates 149 containing 0.2 µg ml -1 streptomycin. This value corresponds to the minimum estimate of the Minimal 150 Selective Concentration (MSC) for spontaneous resistant clones and is ~1/10 the MIC of the 151 susceptible parent strain. Replicate populations, initiated from independent colonies, were grown for 152 either 3 (14 generations) or 4 days (16 generations), after which spores were harvested as above, and 153 then replated at a density of approximately 10 5 spores/plate. Experimental populations were stored at -154 20 °C after every transfer. After ~332 generations replicates of all six populations were in addition 155 serially transferred to plates containing 0.4 µg ml -1 streptomycin, leading to a total of 12 populations. 156
To quantify the evolution of streptomycin resistance through time we plated 10 5 spores of all evolved 157 populations at 50-generation intervals onto SFM supplemented with 2 µg ml -1 of streptomycin. resistant colony was isolated from each 0.2 ug ml -1 population to be used to quantify the fitness of 160 evolved resistant clones. This same clone was subsequently sequenced. 161
162

Fitness assays 163
To assess the fitness of the spontaneous and evolved streptomycin resistant strains, we carried out 164 head-to-head competition experiments between evolved clones and ancestral clones that were 165 differentially marked with an apramycin-resistance cassette 23 . Costs of resistance were quantified by 166 competing strains in the absence of streptomycin, while the MSC of resistant clones was determined 167 by competing strains in the presence of 0, 0.125, 0.25, 0.5 and 1.0 µg ml -1 streptomycin (susceptible 168 clones at or above the MIC were fully displaced). Competition assays were initiated by mixing strains 169 1:1 and then plating 10 5 total spores onto SFM at the indicated streptomycin concentration. To 170 determine the fraction of the inoculum that was apramycin resistant or sensitive, we simultaneously 171 plated a 10 -3 dilution of this mix on SFM and SFM containing 50 µg ml -1 apramycin sulphate 172 (Duchefa Biochemie, The Netherlands). After 4 days of growth at 30 °C the plates were harvested and 173 the numbers of each competitor quantified following plating on SFM agar plates with or without 50 174 µg ml -1 apramycin. Control assays between WT and WT Apr ancestral clones were used to correct for 175 any fitness effects associated with the apramycin marker. Streptomycetes to be sequenced were grown in liquid culture containing 50% YEME/50% TSBS with 188 5 mM MgCl 2 and 0.5% glycine at 30 °C, 250 rpm for 2 days. After centrifugation the pellet was 189 resuspended in TEG-buffer with 1.5 mg ml -1 lysozyme and after 1 hour of incubation at 30 °C the 190 reaction was stopped by adding 0.5 volume of 2M NaCl. DNA was extracted using standard 191 phenol/chloroform extraction, followed by DNA precipitation and washing in isopropanol and 96% 192 ethanol. Dried DNA was resuspended in MQ water and then treated with 50 ug ml -1 of RNase and 193 incubated at 37 °C for 1 hour. Following RNase treatement, the mixture was purified and cleaned as 194 above, after which the purified DNA was washed with 70% ethanol and resuspended in MQ water. To assess the level of streptomycin resistance among streptomycetes in nature, we tested the MICs of 213 85 natural Streptomyces strains originally isolated from the Himalaya and Qinling Mountains 22 . In 214 accordance with literature estimates we found resistance in a substantial fraction of these strains (46%) with low level resistance being more prevalent than high level resistance 25 . This survey 216 confirms that streptomycin resistance is common among streptomycetes in nature and raises questions 217 about the benefits of streptomycin resistance at the presumably low streptomycin concentrations in 218 the soil. Here we use the well-characterized lab strain Streptomyces coelicolor M145 that, with an 219 MIC of 2 ug/ml streptomycin, has negligable resistance to streptomycin, to study the costs and 220 benefits of streptomycin resistance. 221
222
Spontaneous streptomycin resistance 223
To gain insight into fitness effects of streptomycin resistance, we isolated 16 independent clones 224 resistant to at least 2 µg ml -1 streptomycin (the MIC of the susceptible WT parent strain) (Table 1) . 225
The resultant clones had MICs ranging from 4 to 192 µg/ml streptomycin ( Fig. 2 ). Competition 226 experiments between these resistant clones and their susceptible parent in a drug-free environment 227 revealed that although there is significant heterogeneity in the cost of resistance (ANOVA: F 15 = 2.92, 228 p = 0.002), 12 of 16 resistant strains were significantly less fit than the parent, with an average cost of 229 approximately 21% (mean ± SEM = 0.79 ± 0.018). Notably, two highly resistant clones with MICs of 230 196 µg ml -1 streptomycin appeared to have no evident costs of resistance (p > 0.05 for both clones). 231 Across all mutants with significant costs, we found that there was no significant relationship between 232 MIC and fitness (p > 0.05). 233
To estimate the Minimal Selective Concentration (MSC) we carried out competition 234 experiments for a subset of clones across the breadth of streptomycin MIC at increasing streptomycin 235 concentrations and determined the MSC as the antibiotic concentration where the fitness of the 236 susceptible and resistant strain are equal. Figure 3 shows the change in fitness as a function of 237 streptomycin concentration for seven strains, from which we draw two conclusions. First, the fitness 238 of each strain is strongly dependent on the drug concentration to which it is exposed during 239 competition; as anticipated, fitness is lowest in the absence of drugs but increases sharply with small 240 increases in the concentration of streptomycin. Second, there is variation in the MSC of different 241 clones; the lowest MSC we measured (0.202) corresponds to ~1/10 the MIC of streptomycin against 242 the susceptible parent strain while the highest value (0.386) corresponds to ~1/5 the MIC. These data led to the prediction that selection of de novo resistance should be possible at concentrations 244 significantly less than the MIC of wild-type cells. 245
246
Evolution of resistance at sub-MIC concentrations of streptomycin 247
Having shown that antibiotic resistant clones gain significant fitness benefits even at low antibiotic 248 concentrations, we next sought to determine if these same low concentrations could select for de novo 249 resistance. We further aimed to quantify the spectrum of fitness costs of evolved resistant strains, as 250 these are predicted to be lower than the costs of spontaneous resistance. We serially transferred six 251 replicate populations on media containing 0.2 µg ml -1 streptomycin, which corresponds to 1/10 of the 252 MIC of the susceptible parent strain. As shown in Fig. 4 , while the frequency of resistant clones 253 increased by at least 10-fold in three populations, with fixation of resistance in one of the populations, 254 the remaining three populations remained static. We considered two alternative explanations for the 255 apparent absence of resistance in these populations: either resistance mutations had not yet arisen, or 256 alternatively, mutants were present but they were only slowly increasing due to limited benefits at the 257 streptomycin concentrations they faced. To distinguish these possibilities we doubled the drug 258 concentration to 0.4 µg ml -1 after ~ 300 generations and then continued transferring these six new 259 populations in parallel with the original replicates. Consistent with the idea that resistant clones were 260 present, but only slowly increasing, we observed a rapid and significant overall increase in the 261 fraction of resistant cells in these supplemented populations as compared to those evolved at the lower 262 concentration (paired t-test, df = 5, p = 0.028). We confirmed the evolution of de novo streptomycin 263 resistance by measuring the MIC of random clones isolated from evolved populations; clones from all 264 six populations evolved at 0.2 µg ml -1 streptomycin had MIC > 2 µg ml -1 ( Figure 2 ). 265
Evolution of drug resistance below the MIC is predicted to enrich for strains with reduced 266 fitness costs of resistance. This is because resistant strains must still compete with susceptible strains 267 that are inhibited, but not killed, by the antibiotic. To test this prediction we measured the fitness of 268 random resistant clones in the absence of streptomycin that were isolated from the final time point of 269 all replicated populations evolved at 0.2 µg ml -1 streptomycin. As shown in Figure 2 , the fitness of 270 evolved resistant clones is significantly different from the spectrum of fitness effects of spontaneous mutants (GLMM, p < 0.001). While 1 of 6 clones does have fitness costs, the fitness of the remaining 272 five populations is either higher than or indistinguishable from 1. Overall, in contrast to the significant 273 ~21% cost of spontaneous resistance, clones that evolved resistance at sub-MIC streptomycin had an 274 average fitness benefit of ~3%, which did not differ significantly from 1 (Figure 2) . In summary, 275 strains of S. coelicolor evolving at sub-MIC streptomycin can evolve high levels of resistance while 276 simultaneously avoiding the costs associated with this phenotype. 277
278
Genetics of resistance 279
To gain insight into the mechanisms of resistance, we sequenced the genomes of ancestral and 280 resistant strains. Across all resistant strains, we identified a total of 93 mutations: 4 synonymous 281 substitutions, 27 non-synonymous substitutions, 3 insertions, 14 deletions (11 single bp deletions) and 282 45 intergenic mutations. Consistent with extensive convergence across clones, these 93 mutations 283 mapped to only 24 genes (Table 2 ) and 20 intergenic regions (Table S1 ). On average we identified 3.1 284 mutations in the spontaneous mutants, with 1.6 mutations in genes and 1.4 mutations in intergenic 285 regions. As the evolved clones were exposed to sub-MIC levels of streptomycin for 500 generations, 286 it is not surprising that we found significantly more mutations in this set, with an average of 7.4 287 mutations per clone (3.7 mutations in genes and 3.7 in intergenic regions). 288
Since the spontaneous mutants show significant fitness defects, we hypothesized that the 289 mutations identified in this set will be costly resistance mutations, while for the evolved clones we 290 expected to find either the same costly mutations together with others that compensate for these costs 291 or entirely different cost-free resistance mutations. According to our results both outcomes could have 292 occurred in our evolved lineages. Parallel mutation fixation was observed for nine genes. Six of these 293 genes were mutated both in spontaneous and evolved mutants, strongly suggesting that they are 294 associated with streptomycin resistance. Mutations in two of these genes, rsmG and rpsL, are known 295 to confer low 26 and high-level 27 streptomycin resistance in S. coelicolor, respectively. Fourteen strains 296 showed a mutation in either gene, while no strains were mutated in both genes. Eleven strains (10 297 spontaneous and one evolved), with MICs ranging from 12 to 96 µg ml -1 , were found to have a rRNA 28 . Seven of these carried the same effective lesion in a homopolymeric tract of 5 cytosine 300 residues in this gene (26 (C)6>(C)5), resulting in a frame-shift mutation that leads to an early stop 301 codon 26,29 , while the other four show the same non-synonymous substitution. Three clones are 302 mutated in rpsL, encoding r-protein S12; one evolved clone with an MIC of 12 µg ml -1 and two 303 spontaneous clones with an MIC of 192 µg ml -1 , the latter two carrying the same 88K>R mutation that 304 is known to cause high level resistance 29 . Interestingly, these two spontaneous mutants (S13 and S14) 305 are highly resistant to streptomycin, yet neither bears a cost of resistance. 306 While these are the only genes known to cause streptomycin resistance in streptomycetes, the 307 fact that parallel mutations were fixed elsewhere, suggests that these mutations may be causally 308 associated with streptomycin resistance. An interesting case can be made for the two-component 309 system consisting of response regulator DraR (SCO3063) and sensory kinase DraK (SCO3062). 310
While two strains (one spontaneous and one evolved) showed a different mutation in the gene for 311 DraR, another strain was mutated in the gene for DraK. The DraR two-component system has been 312 shown to be involved in the regulation of antibiotic production in S. coelicolor and the structural 313 configuration of the extracellular signal domain of DraK is pH dependent, but its ligand is not known 314 30, 31 . Surprisingly, seven resistant strains have the same mutation in recA, encoding recombinase A 315 that is involved in the homologous recombination of single stranded DNA. This mutation always co-316 occurs with a mutation in rsmG or rpsL; however, when comparing strains that do not have this 317 additional mutation in recA we do not see a difference in MIC or fitness, implying that it may not be 318 involved in streptomycin resistance or compensatory mechanisms. Other parallel mutations occuring 319 both in spontaneous and evolved strains were located in a possible oxidoreductase and another 320 hypothetical protein. 321
Two out of six evolved strains share no mutations with those arising in spontaneous resistant 322 strains, suggesting that resistance in these strains has a different origin. Within the mutations 323 appearing only in the evolved clones, there are three cases of parallelism. A possible chromosome 324 condensation protein is mutated in both of the evolved strains that do not share any mutation with the 325 spontaneous mutants, making it a likely candidate for conferring streptomycin resistance. Two enzyme belonging to the group of penicillin binding proteins involved in cell-wall synthesis. Notably, 328
we identified a mutation in the promoter region of the same gene in a third evolved clone, 101 bp 329 upstream of the predicted translational start site. The third parallel mutation is located in a 330 hypothetical protein. Furthermore, we identified mutations in 12 more genes that were only mutated 331 in evolved clones, none of which were shared with the spontaneous resistant isolates. 332 333 Discussion 334
Despite the appropriate emphasis on the clinical crisis in antibiotic resistance, it is also important to 335 recognize that antibiotic resistance is a natural phenomenon that long predates the modern selective 336 pressure of antibiotic use by man 32 . Genes for antibiotic resistance are commonly found in nature 33 , 337 even in pristine environments untouched by human influence 34, 35 ; however, very little is understood 338 about the processes by which antibiotic resistance arises in these conditions. This has led to questions 339 about the role of antibiotics in soil, where their concentrations are believed to be extremely low, as 340 well as the role of resistance at these sub-lethal concentrations 9,36 . Here we focus on the evolution of 341 antibiotic resistance in the soil bacterium S. coelicolor in response to streptomycin, an antibiotic 342 produced by S. griseus. We first show that streptomycin resistance among natural Streptomyces 343 isolates is widespread, with approximately 50% of strains reaching an MIC greater than S. coelicolor. 344
Next we show that costly antibiotic resistance can be offset at very low streptomycin concentrations; 345 drug concentrations of antibiotics as low as 1/10 the MIC of susceptible strains are sufficient to 346 provide direct fitness benefits for resistant strains. Using experimental evolution, we next find that 347 resistant strains readily evolve during evolution at very low concentrations and furthermore that these 348 evolved mutants are cost-free, in striking contrast to strains that evolved spontaneous resistance that 349 carried fitness costs of more than 20%. Finally, whole genome sequencing revealed that sub-MIC 350 evolved mutants contained a distinct spectrum of mutations from strains emerging at high 351
concentrations. 352
There are several important implications of these results. First, consistent with the results of Evolving resistance at sub-MIC antibiotics by sub-MIC antibiotics, their growth rates are diminished and this provides a broad range of 356 opportunities for resistant cells to increase in frequency 5,6,37 . This has clear relevance to the evolution 357 of resistance in soil, where antibiotic concentrations due to endogenous production by 358 microorganisms, both bacteria and fungi, are believed to be typically too low to inhibit competing 359 susceptible strains 4,8,38 . Thus, even if antibiotics are produced at sub-lethal levels, a suggestion 360 requiring further study, they can nevertheless strongly and directly select for the emergence of 361 resistant cells. Accordingly, emphasis on the MIC of bacteria is likely to be misguided for 362 understanding the roles of both antibiotic production and resistance in soil; instead, emphasis should 363 be reoriented to the MSC in order to determine boundary conditions for the emergence of resistant 364 isolates. 365
Second, our results have clear implications for the persistence of resistant strains. Resistant 366 bacteria that were isolated following exposure to lethal streptomycin concentrations were burdened 367 with significant fitness costs, an outcome widely observed across species 39 . One possibility is that 368 these effects are caused by resistance mutations, e.g. in rpsL or rsmG, that lead to hyper-accurate 369 protein translation and therefore slower growth 40,41 . Alternatively, and specific to Streptomyces, 370 streptomycin resistance can in some cases lead to hyper-production of antibiotics 27,29,42 , although we 371 did not observe any increased susceptibility of our ancestral strain of S. coelicolor to any of the 372 evolved strains. In contrast to bacteria that were selected at high streptomycin concentrations 39,40 , S. 373 coelicolor strains that evolved resistance at sub-MIC doses were cost-free. From an environmental 374 standpoint, this suggests that resistance evolving at sub-MIC antibiotics in soil will persist in the face 375 of competition with susceptible cells, while cells that bear the significant fitness costs of spontaneous 376 resistance would be predicted to decline 8,17 . Consistent with this, and as observed in more detail here, 377 streptomycin resistance is commonly found in nature, with low-level resistance being more prevalent 378 than high-level resistance 25, 43 . Although there are many potential reasons for this, including high 379 densities of S. griseus that are naturally resistant to their own antibiotic 18 , resistance in other species 380 may arise because of the direct benefits resistance provides. From a clinical standpoint, cost-free 381 mutations emerging at sub-MIC antibiotic concentrations are problematic because this could serve to 17 . Certainly, infectious bacteria face a range of antibiotic doses during treatment 5,44 ; if this influences 384 the types of resistance mutations that arise and fix, and in particular their costs, it will be necessary to 385 take this into consideration during the development of treatment protocols. 386
Third, our results suggest that resistance mutations selected at sub-MIC concentrations are 387 distinct from those arising above the MIC. While mutations in genes rsmG and rpsL, known to be 388 associated with streptomycin resistance, were identified in 12 out of 16 spontaneous and 2 out of 6 389 evolved clones, the resistance mechanisms in the other clones remain to be elucidated. Many of the 390 mutations/mutated genes occur in parallel, suggesting that they are directly involved in streptomycin 391 resistance or potentially that these mutations influence the costs of resistance. For example, the DraR-392 K two-component system is mutated in several lineages. Various two-component systems have been 393 implicated in the control of antibiotic production 45 , but as far as we are aware none have been 394 specifically tied to resistance in the absence of the related biosynthetic gene cluster. Further research 395 into the DraR-K response regulon is required to shed light on this important phenomenon. Another 396 intriguing parallel mutation is located in recA and was found in seven sequenced strains. As a 397 disruption of recA in S. coelicolor increases genetic instability 46 , it is possible that this mutation 398 increases the likelihood for subsequent resistance evolution. Despite these cases of parallelism, many 399 evolved lineages carry unique mutations in hypothetical genes or intergenic regions. Moreover, there 400 is little overlap between mutations found in sub-MIC evolved lineages and those selected for 401 spontaneous resistance at higher drug concentrations. This indicates that many routes and mechanisms 402 towards drug resistance are unknown. Also, it may indicate that studying antibiotic resistance at lethal 403 doses provides only part of the spectrum of resistance mutations. At present, the role these mutations 404 play in resistance is unknown; however, these are strong candidate for testing in future work. In 405 addition, these mutations clarify the value of using experimental evolution at sub-MIC drug 406 concentrations to elucidate novel modes of resistance. Finally, we note that in 2 of 16 spontaneously 407 resistant lineages we failed to identify any mutations at all. Although our coverage was high in these 408 clones, the Streptomyces chromosome is very GC rich (>70% G+C content), making assembly may fail to capture duplications that could be highly relevant for resistance evolution 47 . Longer-read 411 sequencing platforms should hopefully address these problems in this system in the future. properties of soils together with the role of other inter-microbial dynamics that influence antibiotic 427 production. It therefore remains a key goal to extend this work to more natural microcosms that 428 include structured soil, as well as including competition with the natural streptomycin producer S. 429 griseus. Second, it remains unclear why de novo antibiotic resistance at sub-MIC streptomycin selects 430 for cost-free mutations. Our genome sequencing has identified several putatively causal mutations for 431 resistance in two well-studied genes; moreover, it has suggested candidate genes that could either 432 compensate for costs of resistance, or alternatively could represent entirely new suites of resistance 433 mechanisms that are intrinsically cost-free. This needs to be followed with more mechanistic studies 434
to determine the precise functional role of these mutations. Finally, it will be important to extend our 435 analyses to the evolution of resistance in natural environments influenced by anthropogenic antibiotic 436 pollution 7,8 . Natural reservoirs for resistance can transfer genes for resistance to clinically relevant 4  5  Table S1 . Mutations in intergenic regions in the spontaneous and evolved clones 6
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